Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Pharmacotherapy|January 30, 2018
The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain DisordersDenise K Patten, Bob G Schultz, Daniel J Berlau
Translational Neurodegeneration|March 7, 2018
The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanismsBob G Schultz, Denise K Patten, Daniel J Berlau
Transplant Infectious Disease : an Official Journal of the Transplantation Society|January 15, 2024
Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator-assigned therapy: A US-based studyBob G Schultz, Michael Bullano, Deepika Paratane, et al.
Journal of Medical Economics|July 3, 2023
Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumabChintal H Shah, Nicole Princic, Kristin A Evans, et al.
Journal of Managed Care & Specialty Pharmacy|October 29, 2021
Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitisBob G Schultz, Ibrahim Diakite, John A Carter, et al.
Journal of Medical Economics|October 3, 2023
Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world dataSepehr Farahbakhshian, Qi Fan, Bob G Schultz, et al.
BMC Gastroenterology|December 6, 2022
Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitisVipul Jairath, Russell D Cohen, Edward V Loftus, et al.
Journal of Comparative Effectiveness Research|February 20, 2025
Comparison of real-world healthcare resource utilization and costs among patients with hereditary angioedema on lanadelumab or berotralstat long-term prophylaxisNicole Princic, Kristin A Evans, Chintal H Shah, et al.
Drugs - Real World Outcomes|January 28, 2025
Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims DataNicole Princic, Kristin A Evans, Chintal H Shah, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 12, 2021
Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension ManagementBob G Schultz, Jessica Tilton, Julie Jun, et al.
Pageof 3